Navigation Links
Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
Date:7/24/2013

NORCROSS, Ga., July 24, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient has been successfully dosed in a Phase 1 clinical trial of GR-MD-02. The first-in-man study will evaluate the safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis.

GR-MD-02 is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of fatty liver disease and fibrosis. Galectin proteins play a major role in diseases that involve scaring of organs such as cancer, and inflammatory and fibrotic disorders. The drug binds to galectin proteins and disrupts their function. Preclinical data has shown that GR-MD-02 has robust treatment effects in reversing fibrosis and cirrhosis.

"The successful first patient dosing in the clinical trial of GR-MD-02 is a critical milestone in Galectin's development program. There are currently no treatments for fatty liver disease with advanced fibrosis; this milestone takes us one step closer to bringing a first-in-class treatment to the millions of Americans suffering from this silent epidemic," said Dr. Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "We anticipate that enrollment of the first cohort of eight patients in the Phase 1 trial will be complete by late summer with initial safety and tolerability results available following the 70 day study period and analysis of the data."

The Phase 1 multi-center, partially-blinded clinical trial will be conducted in 24 patients with fatty liver disease and advanced fibrosis who will r
'/>"/>

SOURCE Galectin Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
2. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
3. Cell Therapeutics to Report Second Quarter Financial Results after Market on July 31, 2013
4. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
5. Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students
6. DART Therapeutics Initiates Study of HT-100 For Duchenne Muscular Dystrophy
7. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
8. Global Antiviral Therapeutics Report - Technologies, Markets and Companies - 2013-2022
9. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
10. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
11. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the company ... 2010 , after the market closes. The press release will be followed by ... to the public via telephone and webcast. During the conference call, the company ... , , ...
... RIVER, N.Y. , April 26 Netsmart Technologies, Inc., ... human services organizations, today named Lakeside Behavioral Healthcare of Orange ... Customer Innovation Award. , ... The Netsmart Customer Innovation Award recognizes organizations for their ...
Cached Medicine Technology:Sangamo BioSciences Announces First Quarter 2010 Conference Call and Webcast 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 2Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 3Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 4Lakeside Behavioral Healthcare Named Winner of First Annual Netsmart Technologies Customer Innovation Award 5
(Date:7/9/2014)... an innovative tool that captures heretofore hidden ways that ... a protein that makes breast cancer cells more likely ... trigger cancer,s spread in part by blocking two other ... that suggests these two disease processes could have unexpected ... July 10 issue of Nature , points to ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at the ... July 17 in Copenhagen, Denmark. Data from the ... transition from cognitive normality to mild cognitive impairment and ... Aging Study , established in 1980 to examine healthy ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... City, July 9, 2014 A study published in ... De Koninck and Robert Bonin, two researchers at Universit ... hypersensitivity using a new method that involves rekindling pain ... could lead to novel means to alleviate chronic pain. ... Universit Laval and Institut universitaire en sant mentale de ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... -- an antibiotic being prescribed to people who may ... growth when taken by pregnant women. Instead, the Centers ... Cipro to pregnant women. The recommendation comes as health ... general population, possibly causing common bacteria to become resistant ...
... study, a trial of a new anti-cancer drug interacts ... a natural product, is being tested as an anti-cancer treatment. ... of the drug on the genes that are activated in ... affected by ceflatonin. These experiments have been done in human ...
... advertisements of prescription drugs, statements about drug benefits ... quantify the medications' expected benefit; instead, they make ... Medical School, Hanover, New Hampshire. // ... is that the medicine is going to prevent ...
... warn that gout can be incredibly painful, and if not ... belief, gout can strike at any time, and for no ... rich food and wine, and women can be affected too, ... affect middle-aged men and some people find an attack follows ...
... pregnant women at risk of the potentially fatal condition ... and E. ,The study, published in the Lancet, found ... pre-eclampsia. ,The condition involves the pregnant mother with ... of the unborn child through the placenta. ,Between ...
... who snore when they are pregnant may be at risk ... lives when they give birth. Around 10% of pregnant women ... can lead to injury or even death in the mother ... pressure by resting or with medication. But drugs may put ...
Cached Medicine News:Health News:Snoring could be a warning 2
... provides superior performance for the diagnosis ... that provides an answer in 6 ... will convince you of this tests ... deliver improved patient care with a ...
Shielding's Wrap-Around / Back Relief Apron transfers the weight from the shoulders to the waist with the aid of a 6" wide elastic belt. Belts may be ordered to fit various sized individuals....
... Shielding's Back Relief Apron has ... transfers the weight from the ... the aid of a 6" ... shoulder strap keeps apron snug. ...
Shielding's Velcro Adjustable Apron has two velcro flaps which aid in relieving weight off the shoulders. Its comfortable fit is attained by varying the position of flaps....
Medicine Products: